What compounds target EPHA3?

BiohacksAI has identified 31 compounds that interact with EPHA3 (EPH receptor A3). Top compounds include: gefitinib, erlotinib, alvocidib, foretinib, tozasertib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is EPHA3 (EPH receptor A3)?

EPHA3 is EPH receptor A3. It is a molecular target for 31 compounds documented in PubMed bioassay data. UniProt ID: P29320. NCBI Gene ID: 2042.

EPHA3

MOLECULAR TARGET

EPH receptor A3

UniProt: P29320 NCBI Gene: 204231 compounds

EPHA3 (EPH receptor A3) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting EPHA3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	alvocidib	4.52	91
4	foretinib	4.34	76
5	tozasertib	4.33	75
6	vandetanib	4.30	73
7	ruxolitinib	4.23	68
8	nilotinib	4.17	64
9	bosutinib	4.08	58
10	doramapimod	4.06	57
11	quizartinib	3.99	53
12	nintedanib	3.61	36
13	canertinib	3.53	33
14	pelitinib	3.50	32
15	tae 684	3.43	30
16	fedratinib	3.40	29
17	linifanib	3.33	27
18	mln 8054	3.33	27
19	sp 600125	3.22	24
20	dasatinib anhydrous	3.09	21
21	lestaurtinib	3.04	20
22	r 406	2.83	16
23	cediranib	2.83	16
24	masitinib	2.77	15
25	kw 2449	2.64	13
26	ast 487	2.56	12
27	su 014813	2.20	8
28	Sorafenib	1.79	5
29	Crizotinib	0.69	1
30	Dasatinib	0.69	1
31	sp600125	0.69	1

About EPHA3 as a Drug Target

EPHA3 (EPH receptor A3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented EPHA3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

EPHA3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.